Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ05105 Thorough QT/QTc Study in Healthy Participants
NCT07708272Phase 1Active, not recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rovadicitinib in myelofibrosis (MF) (4 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Fridericia Placebo-Corrected Change from Baseline in QTc Interval. Started Jul 2026; status: active, not recruiting.
02
Drugs
rovadicitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT07708272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07708272.